Merck, known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration has accepted for priority review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev, an antibody-drug conjugate, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.
November 30, 2023
· 52 min read
